SAGE Therapeutics

Sage shares data on retreatment with depression drug zuranolone
Sage shares data on retreatment with depression drug zuranolone
Fierce Biotech
SAGE Therapeutics
zuranolone
clinical trials
major depressive disorder
Flag link:
Is There Any Hope Left for Sage Therapeutics?
Is There Any Hope Left for Sage Therapeutics?
Motley Fool
SAGE Therapeutics
SAGE-217
SAGE-324
Flag link:
Sage to lay off half of workforce in cost-cutting retrenchment
Sage to lay off half of workforce in cost-cutting retrenchment
BioPharma Dive
SAGE Therapeutics
layoffs
depression
Zulresso
Flag link:
Sage to run 3 new studies to save once-failed depression drug
Sage to run 3 new studies to save once-failed depression drug
Fierce Biotech
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
Sage rethinks SAGE-217 program after phase 3 failure
Sage rethinks SAGE-217 program after phase 3 failure
Fierce Biotech
SAGE Therapeutics
clinical trials
depression
SAGE-217
Flag link:
Here's Why Sage Therapeutics Lost 53.3% in December
Here's Why Sage Therapeutics Lost 53.3% in December
Motley Fool
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Xconomy
SAGE Therapeutics
clinical trials
SAGE-217
major depressive disorder
Flag link:
Sage's new drug starts slow, as Wall Street waits for depression data
Sage's new drug starts slow, as Wall Street waits for depression data
Biopharma Dive
SAGE Therapeutics
postpartum depression
Zulresso
drug launches
Flag link:
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Yahoo/Zacks.com
earnings
biotech
Eyenovia
SAGE Therapeutics
AC Immune
Ascendis
NGM Biopharmaceuticals
Flag link:
Upcoming events – Sage targets depression and Biogen aims for lupus
Upcoming events – Sage targets depression and Biogen aims for lupus
EP Vantage
SAGE Therapeutics
SAGE-217
major depressive disorder
Biogen
BIIB059
lupus
Flag link:
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression
BioSpace
SAGE Therapeutics
treatment-resistant depression
SAGE-217
Flag link:
Marinus leaves the way clear for Sage
Marinus leaves the way clear for Sage
EP Vantage
Marinus Pharma
SAGE Therapeutics
ganaxolone
clinical trials
postpartum depression
Flag link:
Sage strategy for postpartum depression drug Zulresso keys on patient support
Sage strategy for postpartum depression drug Zulresso keys on patient support
Fierce Pharma
SAGE Therapeutics
postpartum depression
patients
Zulresso
Flag link:
2 Biotech Takeout Targets Perfect for Biogen
2 Biotech Takeout Targets Perfect for Biogen
Motley Fool
Biogen
M&A
SAGE Therapeutics
Neurocrine Biosciences
Flag link:
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
Xconomy
SAGE Therapeutics
postpartum depression
Zulresso
brexanolone
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Roche
SAGE Therapeutics
Ligand Pharmaceuticals
brexanolone
Tecentriq
Jazz Pharmaceuticals
JZP-110
Sanofi
Lexicon Pharmaceuticals
Zynquista
PhaseBio
AstraZeneca
Amarin
Leap Therapeutics
Strongbridge
Flag link:
With upcoming PDUFA, Sage proposes $500M follow-on
With upcoming PDUFA, Sage proposes $500M follow-on
BioCentury
SAGE Therapeutics
postpartum depression
Flag link:
Here's Why Sage Therapeutics Gained 48.9% in January
Here's Why Sage Therapeutics Gained 48.9% in January
Motley Fool
SAGE Therapeutics
SAGE-217
postpartum depression
clinical trials
Flag link:
The winners and losers from JPM 2019
The winners and losers from JPM 2019
Biopharma Dive
JPMHC 2019
Loxo Oncology
SAGE Therapeutics
Amarin
FDA
M&A
Flag link:
The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
Motley Fool
Loxo Oncology
SAGE Therapeutics
Insmed
Flag link:

Pages